scholarly journals Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature

2017 ◽  
Vol 67 (6) ◽  
pp. 493-506 ◽  
Author(s):  
Paul J. Hoskins ◽  
Walter H. Gotlieb
2021 ◽  
pp. 67-78
Author(s):  
Varvara Nikolaevna Zhurman ◽  
Natalia Gennadevna Plekhova ◽  
Ekaterina Valeryevna Eliseeva

The article is a review of the literature, which analyzes the data on the role of cells of the immune system, cytokines and other biologically active substances secreted by them in the interstitial space of an ovarian tumor. The emphasis is made on the mechanism of realization by immune cells of the stimulating and suppressing action on the development of the tumor. Considerable attention is paid to the prognostic role of immune cells in the development of epithelial ovarian cancer.


2016 ◽  
Vol 141 ◽  
pp. 194 ◽  
Author(s):  
C.L. Swanson ◽  
J.M. Beissel ◽  
A. Kumar ◽  
M. Wick ◽  
G. Beek ◽  
...  

2020 ◽  
Vol 156 (3) ◽  
pp. e22
Author(s):  
E. Coulter ◽  
A. Barrie ◽  
C. Saenz ◽  
S. Plaxe ◽  
R. Eskander ◽  
...  

Author(s):  
Laura Knabben ◽  
Sara Imboden ◽  
Michel D. Mueller

AbstractBackgroundClinical practices and testing strategies in patients with ovarian cancer differ worldwide. We therefor wanted to give an overview over the current data to advise best clinical practice.Materials and methodsA systematic review of the literature was performed with the aim to define which ovarian cancer patients to refer for genetic counseling and how to perform genetic testing. We also discuss the timing of genetic testing and clinical relevance of the BRCA mutation status.ResultsThe germline mutation rate in patients with ovarian cancer is high, independent of family history, age at diagnosis and histology. BRCA mutation carriers with ovarian cancer have improved survival rates. In recurrent ovarian cancer treatment by poly ADP ribose polymerase (PARP) inhibitors improves the disease-free survival in patients with BRCA mutations or homologous recombination deficiency with hazard ratios up to 0.23. But also patients with BRCA wild type show a benefit. The recently published SOLO-1 trial demonstrated a significant benefit for patients with germline BRCA mutations in the first line setting. By tumor testing about 7% additional BRCA mutations can be found but the somatic testing and interpretation of the results remains a challenge. Despite the clinical impact, analysis of our own data and also international publications show insufficient referral rates for genetic counseling.ConclusionsGenetic testing in ovarian cancer has a prognostic and predictive value. Referral rates must be improved.


2013 ◽  
Vol 31 (31_suppl) ◽  
pp. 236-236
Author(s):  
Hilary B. Kershberg ◽  
Monica Alvarado ◽  
Jaime L. Natoli ◽  
Emily Parkhurst ◽  
Hui Zhou ◽  
...  

236 Background: Diagnosis of breast cancer at a young age is an indication for genetic counseling and possible BRCA testing. However, not all women with this early diagnosis are referred for genetic counseling, especially if they do not have a family history of breast or ovarian cancer. Methods: The genetics department in Kaiser Permanente Southern California (KPSC) provides clinical genetic services in an integrated health care system serving over 3.6 million members. Using data from the KPSC tumor registry, the KPSC EMR system, and a departmental cancer test results database, we identified 454 women diagnosed with early breast cancer (<46 years) between September 2005 and September 2010 who had not received genetic counseling. We contacted these women with a letter and/or phone call offering a genetics consultation, and we offered BRCA testing to all those who came for counseling. Results: 142 women (31%) came in for genetic counseling, and 312 women (69%) declined, did not keep their appointment, or never responded. Hispanics were more likely to schedule and keep an appointment than Caucasians (OR=1.35, 95% CI, 0.79-2.31), although this was not statistically significant. Of those who came in for counseling, African Americans were significantly less likely to accept genetic testing than Caucasians (OR=0.31, 95% CI, 0.10-0.98).Of the 142 patients who were counseled, 122 (86%) accepted testing. We identified 6 patients (5%) who were positive for a deleterious BRCA mutation and 6 patients (5%) who had a variant of uncertain significance. Of the 6 women with deleterious mutations, only 1 had a first-degree relative with breast or ovarian cancer, and 4 had mutation probabilities <10%. Conclusions: This project demonstrates how an integrated care approach and EMR system provide an opportunity to identify and contact women who are at increased risk for inherited cancer susceptibility.


Sign in / Sign up

Export Citation Format

Share Document